Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

Inclusion Criteria:

- Men or women at least 18 years of age at time of screening

- Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization

- Moderate to severe psoriasis as defined at baseline by:

- PASI score of 12 or greater

- Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 -
4) and,

- Body Surface Area affected by plaque-type psoriasis of 10% or greater

- Chronic plaque-type psoriasis patients who have previously received phototherapy or
systemic psoriasis therapy at least once or who are candidates for such therapies in
the opinion of the investigator.

Exclusion Criteria:

- Forms of psoriasis other than chronic plaque-type

- Drug-induced psoriasis

- Ongoing use of prohibited psoriasis treatments

- Previous exposure to adalimumab

- Active ongoing inflammatory diseases other than psoriasis that might confound the
evaluation of the benefit of treatment with adalimumab

Other In-/Exclusion criteria may apply